CYBIN INC.
HELPNext catalyst
Phase 3 — HLP003
Get an email about HELP's next catalysts
Track CYBIN (HELP) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (conference, earnings, Phase 3 readout).See the timeline
4 upcoming, 0 past
Conference Presentation - HLP003
For Adjunctive treatment of major depressive disorder. Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on November 9, 2026 at 3:00 p.m. EDT, with a live webcast and replay available.
SourceHELP Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.67 | FQ end Sep/2026 | Call: tbd
Phase 3 — HLP003
For adjunctive treatment of major depressive disorder. Helus Pharma's HLP003, a breakthrough-designated depression drug, has reached 86% enrollment in its Phase 3 APPROACH trial with topline data expected later in 2026.
SourceCYB003 Phase 3 Est. Readout (EMBRACE)
Estimated primary completion for CYB003 trial (NCT06793397) in Major Depressive Disorder (MDD). Topline data typically follows completion by weeks to months.
SourceHow HELP's past catalysts played out
Market Overview
Stock performance and key metrics
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in CYBIN INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in CYBIN INC.'s (HELP) pipeline across Phase 3, Phase 2. Its lead program is CYB003 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CYBIN INC.'s next FDA catalyst?→
CYBIN INC.'s (HELP) next tracked catalyst is a Phase 3 readout expected Dec 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HELP biotech catalysts?→
Add HELP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CYBIN INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.